#eli-lilly

3 articles tagged #eli-lilly.

Ready to compare providers? Take the 2-minute match quiz or see the cheapest GLP-1 options.

#2026 4#503a 1#503b 2#FDA 1#alternatives 1#ban 1#before-and-after 1#beginners 2#brand-name 3#bridge-program 1#cagrilintide 1#cagrisema 1#comparison 2#compounded 8#compounded-semaglutide 1#compounded-tirzepatide 1#compounding-ban 1#copay 1#cost 13#coupon 1#coverage 1#diabetes 1#diet 1#dosage 1#eli-lilly 3#enforcement 1#enrollment 1#fact-check 1#fda 3#fda-approval 1#flat-rate 1#foundayo 7#framework 1#glp-1-patches 1#glucose-monitors 1#guide 1#hhs 1#hims 1#how-to-get 1#injectable 7#injection 1#insulin-resistance 1#insurance 11#ivy-rx 1#ivyrx 1#legality 1#liraglutide 1#medicaid 1#medicare 5#mounjaro 6#news 2#novo-nordisk 2#oral-glp1 6#oral-semaglutide 1#orforglipron 4#ozempic 7#pcos 1#pill 1#pipeline 1#policy 1#prior-authorization 2#regulation 2#results 1#rfk 1#ro 1#safety 3#savings-card 1#schedule 1#semaglutide 19#shortage 1#side-effects 9#supplements 1#surmount 2#surmount-5 1#telehealth-enforcement 1#telehealth-review 1#timeline 1#tirzepatide 18#type-2-diabetes 1#warning-letters 1#wegovy 16#wegovy-hd 1#wegovy-pill 3#weight-loss 26#without-insurance 1#zepbound 17
Editorial still-life illustrating Foundayo and Wegovy pill comparison for weight loss
AnalysisComparisonsJune 16, 2026• 20 min read

Foundayo vs Wegovy Pill (2026): 16.6% vs 12.4% Weight Loss, $149 vs $1,349/mo Self-Pay

Updated June 16, 2026: CVS Caremark removed Foundayo's new-to-market block June 1 (~25–30M commercial lives can now be covered); Zepbound becomes co-preferred Oct 1; Medicare GLP-1 Bridge covers Foundayo at $50/mo from July 1. Verified IQVIA launch data runs through Week 3 (1,390 → 3,707 → 5,612 Rx); later weeks are competing analyst estimates (Citi ~16,000 vs Jefferies ~11,700 for late May) that undercount telehealth. Oral Wegovy produces 16.6% weight loss vs Foundayo's 12.4%; Foundayo starts at $149/mo self-pay with no fasting requirement.

Editorial lifestyle photograph illustrating a guide to Foundayo orforglipron oral GLP-1
GuideGuidesApril 29, 2026• 14 min read

Foundayo (Orforglipron) Guide 2026: from $149/mo Self-Pay, 12.4% Weight Loss, No Fasting Required

Updated April 29, 2026: Foundayo (orforglipron) is the first non-peptide GLP-1 pill for weight loss, FDA-approved April 1, 2026. Produces 12.4% body weight loss over 72 weeks per ATTAIN-1 trial. ACHIEVE-4 (April 2026): 57% lower all-cause death vs insulin glargine (HR 0.43, 2,700 patients). Self-pay starts at $149/month (starting dose) via LillyDirect, $299/month at maintenance doses. No food or water restrictions, take any time.

Featured Partners

Four affiliate partners we feature, we may earn a commission.

Yucca Health

7.7/10
$146/mo·Compounded
Visit Yucca HealthReview

Gala

7.2/10
$149/mo·Brand & Compounded
Visit GalaReview

TrimRx

7.8/10
$149/mo·Compounded
Visit TrimRxReview

SkinnyRx

7.3/10
$199/mo·Compounded
Visit SkinnyRxReview

Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. The objective ranking (by methodology score) and full methodology are at glp1picks.com/best.